CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Sale | −3,003 | $279.15 | $838K | 4,520 |
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Sale | −2,620 | $279.96 | $733K | 1,900 |
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Sale | −1,000 | $280.92 | $281K | 900 |
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Sale | −400 | $282.13 | $113K | 500 |
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Sale | −400 | $283.43 | $113K | 100 |
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Sale | −100 | $284.65 | $28K | 0 |
| 2022-12-23 | Sukhija Remy Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) | −30,000 | 30,000 | ||
| 2022-08-10 | Lynch Brian Joseph SVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2022-06-16 | BATE KENNETH Director | Grant or award · Stock Option (Right to Buy) | +9,470 | 9,470 | ||
| 2022-06-16 | MILLIGAN DAVID V Director | Grant or award · Stock Option (Right to buy) | +9,470 | 9,470 | ||
| 2022-06-16 | CRAVES FRED B Director | Grant or award · Stock Option (Right to Buy) | +9,470 | 9,470 | ||
| 2022-06-16 | Levy Richard S Director | Grant or award · Stock Option (Right to buy) | +9,470 | 9,470 | ||
| 2022-06-16 | Daly James M Director | Grant or award · Stock Option (Right to Buy) | +9,470 | 9,470 | ||
| 2022-06-16 | Gollust Keith R Director | Grant or award · Stock Option (Right to Buy) | +9,470 | 9,470 | ||
| 2022-02-24 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award · Call Option | +12,250 | 12,250 | ||
| 2022-02-22 | Howarth Alex G. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-02-22 | Lynch Brian Joseph SVP and General Councel | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-02-22 | Sukhija Remy Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-02-22 | Taub Rebecca See Remarks | Grant or award · Stock Option (Right to Buy) | +61,500 | 61,500 | ||
| 2022-02-22 | FRIEDMAN PAUL A Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 |
Page 51 of 82 · 1,629 trades